Cargando…

Ivacaftor modifies cystic fibrosis neutrophil phenotype in subjects with R117H residual function CFTR mutations

CFTR modulation leads to changes in neutrophil phenotype even in patients with residual function CFTR mutations https://bit.ly/2EUk7xH

Detalles Bibliográficos
Autores principales:	Hardisty, Gareth R., Law, Sheonagh M., Carter, Suzanne, Grogan, Brenda, Singh, Pradeep K., McKone, Edward F., Gray, Robert D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2021
Materias:	Agora
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7817919/ https://www.ncbi.nlm.nih.gov/pubmed/32855222 http://dx.doi.org/10.1183/13993003.02161-2020

Ejemplares similares

Ivacaftor decreases monocyte sensitivity to interferon-γ in people with cystic fibrosis
por: Hisert, Katherine B., et al.
Publicado: (2020)

Combining Ivacaftor and Intensive Antibiotics Achieves Limited Clearance of Cystic Fibrosis Infections
por: Durfey, Samantha L., et al.
Publicado: (2021)

Eradication success for non-tuberculous mycobacteria in children with cystic fibrosis
por: Hughes, Dominic A., et al.
Publicado: (2021)

Bile acid aspiration in people with cystic fibrosis before and after lung transplantation
por: Brodlie, Malcolm, et al.
Publicado: (2015)

Low socioeconomic status is associated with worse lung function in the Danish cystic fibrosis population
por: Taylor-Robinson, David C., et al.
Publicado: (2014)

An observational study of the lung clearance index throughout childhood in cystic fibrosis: early years matter
por: Davies, Gwyneth, et al.
Publicado: (2020)

Neutrophil extracellular traps and the dysfunctional innate immune response of cystic fibrosis lung disease: a review
por: Law, Sheonagh M., et al.
Publicado: (2017)

Residual symptoms and lower lung function in patients recovering from SARS-CoV-2 infection
por: Trinkmann, Frederik, et al.
Publicado: (2021)

The use of ivacaftor in CFTR mutations resulting in residual functioning protein
por: Guigui, S., et al.
Publicado: (2016)

CFTR Modulator Therapy Enhances Peripheral Blood Monocyte Contributions to Immune Responses in People With Cystic Fibrosis
por: Hisert, Katherine B., et al.
Publicado: (2020)

Proteinase release from activated neutrophils in mechanically ventilated patients with non-COVID-19 and COVID-19 pneumonia
por: Seren, Seda, et al.
Publicado: (2021)

Cystic fibrosis drug ivacaftor stimulates CFTR channels at picomolar concentrations
por: Csanády, László, et al.
Publicado: (2019)

Non‐pulmonary CFTR‐related symptom improvement with ivacaftor in p.Phe508del/p.Arg117His (7T) cystic fibrosis
por: Kuek, Stephanie L., et al.
Publicado: (2022)

The magnitude of ivacaftor effects on fluid secretion via R117H-CFTR channels: Human in vivo measurements
por: Char, Jessica E., et al.
Publicado: (2017)

A Little CFTR Goes a Long Way: CFTR-Dependent Sweat Secretion from G551D and R117H-5T Cystic Fibrosis Subjects Taking Ivacaftor
por: Char, Jessica E., et al.
Publicado: (2014)

Acute respiratory distress syndrome is associated with impaired alveolar macrophage efferocytosis
por: Mahida, Rahul Y., et al.
Publicado: (2021)

Registry-based study in people with cystic fibrosis and an R117H variant treated with ivacaftor
por: Higgins, Mark, et al.
Publicado: (2023)

Ivacaftor in Omani children with cystic fibrosis caused by p.Ser549Arg CFTR mutation
por: Al Oraimi, Sumaya, et al.
Publicado: (2022)

Job strain and COPD exacerbations: an individual-participant meta-analysis
por: Heikkilä, Katriina, et al.
Publicado: (2014)

Does a single Pseudomonas aeruginosa isolation predict COPD mortality?
por: Boutou, Afroditi K., et al.
Publicado: (2014)

Supporting progress towards the post-2015 targets and regional tuberculosis elimination: a statement of intent from the third meeting of the Asian TB Experts Community
por: Mori, Toru, et al.
Publicado: (2015)

Noninterventional statistical comparison of BTS and CHEST guidelines for size and severity in primary pneumothorax
por: Nikolić, Marko Z., et al.
Publicado: (2015)

Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid
por: Wells, Charles D., et al.
Publicado: (2015)

Numbers needed to treat to prevent tuberculosis
por: Matteelli, Alberto, et al.
Publicado: (2015)

Breathlessness, physical activity and sustainability of healthcare
por: Aitsi-Selmi, Amina, et al.
Publicado: (2015)

Urokinase plasminogen activator receptor polymorphisms and airway remodelling in asthma
por: Ierodiakonou, Despo, et al.
Publicado: (2016)

Monitoring toxicity in individuals receiving treatment for latent tuberculosis infection: a systematic review versus expert opinion
por: Sotgiu, Giovanni, et al.
Publicado: (2015)

Respiratory decline is integral to disease progression in Huntington's disease
por: Jones, Una, et al.
Publicado: (2016)

Variation in policy and practice of adolescent tuberculosis management in the WHO European Region
por: Blok, Nick, et al.
Publicado: (2016)

Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges
por: Tadolini, Marina, et al.
Publicado: (2016)

First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline
por: Tadolini, Marina, et al.
Publicado: (2016)

Tuberculosis prevention must integrate technological and basic care innovation
por: Mason, Paul H., et al.
Publicado: (2016)

Cross border, highly individualised treatment of a patient with challenging extensively drug-resistant tuberculosis
por: Akkerman, Onno W., et al.
Publicado: (2018)

DNA methylation modules in airway smooth muscle are associated with asthma severity
por: Perry, Mark M., et al.
Publicado: (2018)

Chronic breathlessness: re-thinking the symptom
por: Macnaughton, Jane, et al.
Publicado: (2018)

Eligibility for shorter treatment of multidrug-resistant tuberculosis in the European Union
por: van der Werf, Marieke J., et al.
Publicado: (2017)

Early outcomes in MDR-TB and XDR-TB patients treated with delamanid under compassionate use
por: Hafkin, Jeffrey, et al.
Publicado: (2017)

Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis
por: van Manen, Mirjam J.G., et al.
Publicado: (2017)

3-month daily rifampicin and isoniazid compared to 6- or 9-month isoniazid for treating latent tuberculosis infection in children and adolescents less than 15 years of age: an updated systematic review
por: Assefa, Yibeltal, et al.
Publicado: (2018)

MEK5 promotes lung adenocarcinoma
por: Sánchez-Fdez, Adrián, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_iou3be5tfl8eq0iepurfu0uonm